[{"address1": "401-420, Biomedical Park", "address2": "4th Floor 185 South Avenue TEDA West District", "city": "Tianjin", "zip": "300457", "country": "China", "phone": "86 022 5821 3600", "fax": "86 022 5821 3677", "website": "https://www.cansinotech.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.", "fullTimeEmployees": 1494, "companyOfficers": [{"maxAge": 1, "name": "Dr. Xuefeng  Yu Ph.D.", "age": 58, "title": "Co-Founder, Executive Chairman, CEO & GM", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 556484, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tao  Zhu Ph.D.", "age": 50, "title": "Co-Founder, Deputy GM & Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 620202, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dongxu  Qiu MBA, Ph.D.", "age": 63, "title": "Co-Founder, Executive VP & Deputy GM", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 524484, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shou-Bai  Chao Ph.D.", "age": 59, "title": "COO, Deputy GM & Executive Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 551151, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jing  Wang", "age": 42, "title": "Chief Commercial Officer, Deputy GM & Executive Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 556624, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chunlin  Xin", "title": "Senior Director of New Technology Department", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yonghui  Wu", "title": "Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jin  Cui", "age": 36, "title": "Board Secretary", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ming King  Chiu FCIS, FCS", "age": 46, "title": "Joint Company Secretary", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 2, "shareHolderRightsRisk": 9, "overallRisk": 5, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.83, "open": 2.83, "dayLow": 2.83, "dayHigh": 2.83, "regularMarketPreviousClose": 2.83, "regularMarketOpen": 2.83, "regularMarketDayLow": 2.83, "regularMarketDayHigh": 2.83, "exDividendDate": 1657670400, "beta": 0.518, "volume": 100, "regularMarketVolume": 100, "averageVolume": 90, "averageVolume10days": 10, "averageDailyVolume10Day": 10, "bid": 2.05, "ask": 2.57, "bidSize": 40000, "askSize": 381200, "marketCap": 948239808, "fiftyTwoWeekLow": 1.86, "fiftyTwoWeekHigh": 3.55, "priceToSalesTrailing12Months": 2.557196, "fiftyDayAverage": 2.298, "twoHundredDayAverage": 2.41475, "currency": "USD", "enterpriseValue": -1085825152, "floatShares": 127556126, "sharesOutstanding": 132671000, "heldPercentInsiders": 0.26748, "heldPercentInstitutions": 0.155, "bookValue": 20.67, "priceToBook": 0.095791005, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -1513280512, "trailingEps": -0.49, "enterpriseToRevenue": -2.928, "enterpriseToEbitda": 0.792, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CASBF", "underlyingSymbol": "CASBF", "shortName": "CANSINO BIOLOGICS INC", "longName": "CanSino Biologics Inc.", "firstTradeDateEpochUtc": 1577975400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "380a74d7-49df-3aa4-a750-db436ab6cd84", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.98, "recommendationKey": "none", "totalCash": 4014792192, "totalCashPerShare": 16.251, "ebitda": -1370357504, "totalDebt": 2439820288, "quickRatio": 2.197, "currentRatio": 2.389, "totalRevenue": 370812352, "debtToEquity": 47.779, "revenuePerShare": 1.5, "returnOnAssets": -0.10272, "returnOnEquity": -0.32371, "freeCashflow": -691070272, "operatingCashflow": -671018112, "revenueGrowth": 0.137, "grossMargins": -1.1085501, "operatingMargins": -0.98856, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]